Results 231 to 240 of about 82,980 (311)

Delta-like Ligand 3-Directed ²²⁵Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models. [PDF]

J Nucl Med
Hoang TT, Bauer D, Ingham A, Miranda IC, Carter LM, Michel A, De Gregorio R, Welk J, Zhong H, Poirier JT, Morris MJ, Bodei L, Rudin CM, Tendler S, Lewis JS.   +14 more
europepmc   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source

Fungal Infections in Pediatric Patients With Hematologic Malignancies and Stem Cell Transplantation: Impact on the Upper and Lower Respiratory Systems. [PDF]

Can J Infect Dis Med Microbiol
Pourghasem M, Tabatabaii SA, Modarresi SZ, Jafari Nodoushan A, Fadavi N, Soflaee M, Hosseini Vajari A, Khazaii F, Shahhosseini B, Fakhimi Derakhshan K, Sadat Mansouri S.   +10 more
europepmc   +1 more source

Quality control of hematologic test.

Japanese journal of MHTS, 1987
openaire   +2 more sources

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Feasibility of Outpatient Follow-Up After High-Dose Cytarabine Consolidation in Patients With Acute Myeloid Leukemia. [PDF]

Cureus
Ullah MF, Kibria MG, Rahman KF, Hossen MZ, Sultana N, Kabir AL, Biswas AR.   +6 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Longitudinal effects of inpatient music therapy dosage on pain intensity and opioid utilization among patients with hematologic or oncologic conditions: a retrospective cohort study. [PDF]

Support Care Cancer
Rodgers-Melnick SN, Gunzler D, Love TE, Koroukian SM, Beno M, Rao S, Razzak R, Dusek JA, Rose J.   +8 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source